Role of contractile reserve as a predictor of mortality in low-flow, low-gradient severe aortic stenosis following transcatheter aortic valve replacement.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 03 2019
Historique:
received: 31 05 2018
revised: 14 08 2018
accepted: 09 09 2018
pubmed: 4 10 2018
medline: 15 4 2020
entrez: 4 10 2018
Statut: ppublish

Résumé

The aim of this study was to determine the prognostic value of contractile reserve (CR) at baseline in patients with low-flow, low-gradient severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). Patients with severe AS, left ventricular dysfunction, and low transaortic gradient are at high risk for mortality during surgical aortic valve replacement (SAVR). Furthermore, patients without CR have been shown to have perioperative mortality comparable to that of patients treated medically for severe AS. We retrospectively analyzed patients who underwent TAVR with a diagnosis of low-gradient severe AS (mean transvalvular aortic gradient < 40 mmHg, LVEF < 50%, and AVA ≤ 1.0 cm From 2008 to 2016, 61 patients with low-gradient severe AS underwent TAVR and had pre-TAVR DSE. CR was present in 31 patients (51%) and absent in 30 (49%). There was no significant difference between the two groups in baseline demographics, medical history, access site, or types of valves. All-cause mortality was similar in both groups at 30 days (13% with CR vs 10% without CR, P = 1.00) and 1 year (29% with CR vs 33% without CR, HR 1.20, 95% CI 0.49-2.96, P = 0.69). In patients with low-flow, low-gradient severe AS undergoing TAVR, the presence or absence of CR does not predict all-cause mortality at 30 days or 1 year.

Sections du résumé

OBJECTIVES
The aim of this study was to determine the prognostic value of contractile reserve (CR) at baseline in patients with low-flow, low-gradient severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR).
BACKGROUND
Patients with severe AS, left ventricular dysfunction, and low transaortic gradient are at high risk for mortality during surgical aortic valve replacement (SAVR). Furthermore, patients without CR have been shown to have perioperative mortality comparable to that of patients treated medically for severe AS.
METHODS
We retrospectively analyzed patients who underwent TAVR with a diagnosis of low-gradient severe AS (mean transvalvular aortic gradient < 40 mmHg, LVEF < 50%, and AVA ≤ 1.0 cm
RESULTS
From 2008 to 2016, 61 patients with low-gradient severe AS underwent TAVR and had pre-TAVR DSE. CR was present in 31 patients (51%) and absent in 30 (49%). There was no significant difference between the two groups in baseline demographics, medical history, access site, or types of valves. All-cause mortality was similar in both groups at 30 days (13% with CR vs 10% without CR, P = 1.00) and 1 year (29% with CR vs 33% without CR, HR 1.20, 95% CI 0.49-2.96, P = 0.69).
CONCLUSION
In patients with low-flow, low-gradient severe AS undergoing TAVR, the presence or absence of CR does not predict all-cause mortality at 30 days or 1 year.

Identifiants

pubmed: 30280469
doi: 10.1002/ccd.27914
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

707-712

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Kyle D Buchanan (KD)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Toby Rogers (T)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Arie Steinvil (A)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Edward Koifman (E)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Linzhi Xu (L)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Rebecca Torguson (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Petros G Okubagzi (PG)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Christian Shults (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Augusto D Pichard (AD)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Itsik Ben-Dor (I)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Lowell F Satler (LF)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Ron Waksman (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Federico M Asch (FM)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH